ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary ...

Researchers make use of small-angle X-ray scattering to reveal potential-dependent structural changes in redox enzymes used ...

This study presents efficient CaO/ZnO composite catalysts for biodiesel production from soybean oil, achieving 99% conversion ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a ...

Dark oxygen, a newly identified form of oxygen, raises questions about life in extreme environments and its implications for ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

A change is called irreversible if it cannot be changed back again. Many chemical reactions are irreversible. In a chemical reaction, new materials are always formed. Sometimes these new materials ...

The analyst continues to view Ingrezza as the gold-standard pharmacotherapy for tardive dyskinesia (TD), given its once-daily dosing, no need for long dose titration intervals, and lack of a ...

Ascendis Pharma (ASND) reported its fourth-quarter 2024 earnings, highlighting a significant revenue increase and a positive market reaction. The company posted total revenue of €173.9 million for the ...

All wines have some volatile acidity, which can add to a wine’s complexity at low levels. At what point does it become a ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...